Verastem taking dafactinib early to Japan
This article was originally published in Scrip
Executive Summary
It may be just a small Phase I study but Verastem is excited about beginning the clinical development of its lead candidate defactinib (VS-6063) in Japan for its initial indication of malignant pleural mesothelioma.